218 related articles for article (PubMed ID: 33123756)
1. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.
Dao T; Klatt MG; Korontsvit T; Mun SS; Guzman S; Mattar M; Zivanovic O; Kyi CK; Socci ND; O'Cearbhaill RE; Scheinberg DA
Cancer Immunol Immunother; 2021 May; 70(5):1189-1202. PubMed ID: 33123756
[TBL] [Abstract][Full Text] [Related]
2. T-cell Responses to
Deniger DC; Pasetto A; Robbins PF; Gartner JJ; Prickett TD; Paria BC; Malekzadeh P; Jia L; Yossef R; Langhan MM; Wunderlich JR; Danforth DN; Somerville RPT; Rosenberg SA
Clin Cancer Res; 2018 Nov; 24(22):5562-5573. PubMed ID: 29853601
[No Abstract] [Full Text] [Related]
3. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations.
Hansen UK; Ramskov S; Bjerregaard AM; Borch A; Andersen R; Draghi A; Donia M; Bentzen AK; Marquard AM; Szallasi Z; Eklund AC; Svane IM; Hadrup SR
Front Immunol; 2020; 11():373. PubMed ID: 32226429
[TBL] [Abstract][Full Text] [Related]
5. Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.
Tsuji T; Matsuzaki J; Ritter E; Miliotto A; Ritter G; Odunsi K; Old LJ; Gnjatic S
PLoS One; 2011; 6(8):e23651. PubMed ID: 21858191
[TBL] [Abstract][Full Text] [Related]
6. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
7. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
8. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.
Keogh E; Fikes J; Southwood S; Celis E; Chesnut R; Sette A
J Immunol; 2001 Jul; 167(2):787-96. PubMed ID: 11441084
[TBL] [Abstract][Full Text] [Related]
9. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.
Sinnathamby G; Lauer P; Zerfass J; Hanson B; Karabudak A; Krakover J; Secord AA; Clay TM; Morse MA; Dubensky TW; Brockstedt DG; Philip R; Giedlin M
J Immunother; 2009 Oct; 32(8):856-69. PubMed ID: 19752748
[TBL] [Abstract][Full Text] [Related]
10. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
Olson BM; Frye TP; Johnson LE; Fong L; Knutson KL; Disis ML; McNeel DG
Cancer Immunol Immunother; 2010 Jun; 59(6):943-53. PubMed ID: 20140431
[TBL] [Abstract][Full Text] [Related]
11. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
[TBL] [Abstract][Full Text] [Related]
12. Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.
Wickström SL; Lövgren T; Volkmar M; Reinhold B; Duke-Cohan JS; Hartmann L; Rebmann J; Mueller A; Melief J; Maas R; Ligtenberg M; Hansson J; Offringa R; Seliger B; Poschke I; Reinherz EL; Kiessling R
Front Immunol; 2019; 10():2766. PubMed ID: 31921104
[TBL] [Abstract][Full Text] [Related]
13.
Schmidt J; Guillaume P; Dojcinovic D; Karbach J; Coukos G; Luescher I
J Biol Chem; 2017 Jul; 292(28):11840-11849. PubMed ID: 28536262
[TBL] [Abstract][Full Text] [Related]
14. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
[TBL] [Abstract][Full Text] [Related]
15. ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.
Sinnathamby G; Zerfass J; Hafner J; Block P; Nickens Z; Hobeika A; Secord AA; Lyerly HK; Morse MA; Philip R
Clin Exp Immunol; 2011 Mar; 163(3):324-32. PubMed ID: 21175594
[TBL] [Abstract][Full Text] [Related]
16. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
[TBL] [Abstract][Full Text] [Related]
17. Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire.
Millar DG; Yang SYC; Sayad A; Zhao Q; Nguyen LT; Warner K; Sangster AG; Nakatsugawa M; Murata K; Wang BX; Shaw P; Clarke B; Bernardini MQ; Pugh T; Thibault P; Hirano N; Perreault C; Ohashi PS
Cancer Immunol Immunother; 2023 Jul; 72(7):2375-2392. PubMed ID: 36943460
[TBL] [Abstract][Full Text] [Related]
18. Altered HLA-A2-restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma.
Ye C; Lin S; Hong J; Liu F; Guo G; Chen S; Zhou Z; Lin W; Li J; Ye Y
Eur J Immunol; 2023 May; 53(5):e2250054. PubMed ID: 36794567
[TBL] [Abstract][Full Text] [Related]
19. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
20. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
Hoffmann TK; Loftus DJ; Nakano K; Maeurer MJ; Chikamatsu K; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2002 Feb; 168(3):1338-47. PubMed ID: 11801674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
